Australia Markets closed

Antisense Therapeutics Limited (ANP.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1100+0.0100 (+10.00%)
At close: 04:10PM AEST

Antisense Therapeutics Limited

14 Wallace Avenue
Level 1
Toorak, VIC 3142
Australia
61 3 9827 8999
https://www.antisense.com.au

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICDCEO, MD & Director459.49kN/AN/A
Mr. Phillip Allen Hains BBus(Acc), CA, MBACFO & Joint Company Sec.99kN/A1959
Ms. Alicia MellorsJoint Company Sec.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.

Corporate governance

Antisense Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.